Primary Biliary Cholangitis in 2025: A New Frontier
- 29 May 2025
- journal article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (12) , 2746-2749
Abstract
An abstract is unavailable. This article is available as a PDF only.Keywords
This publication has 17 references indexed in Scilit:
- Primary biliary cholangitisThe Lancet, 2024
- A Phase 3 Trial of Seladelpar in Primary Biliary CholangitisNew England Journal of Medicine, 2024
- Efficacy and Safety of Elafibranor in Primary Biliary CholangitisNew England Journal of Medicine, 2024
- Population Dose–Response‐Time Analysis of Itch Reduction and Patient‐Reported Tolerability Supports Phase III Dose Selection for LinerixibatClinical Pharmacology & Therapeutics, 2023
- Effect on lipid profile and clinical outcomes of obeticholic acid for the treatment of primary biliary cholangitis and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysisClinics and Research in Hepatology and Gastroenterology, 2023
- Systemic Complications of Primary Biliary CholangitisClinics in Liver Disease, 2023
- Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled TrialGastroenterology, 2021
- Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver DiseasesHepatology, 2018
- EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitisJournal of Hepatology, 2017
- A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary CholangitisNew England Journal of Medicine, 2016